Superiority of synovial membrane mesenchymal stem cells in chondrogenesis, osteogenesis, myogenesis and tenogenesis in a rabbit model

Bami, Myrto; Sarlikiotis, Thomas; Milonaki, Mandy; Vikentiou, Myrofora; Konsta, Evgenia; Kapsimali, Violetta; Pappa, Vasiliki; Koulalis, Dimitrios; Johnson, Elizabeth O.; Soucacos, Panayotis N.

doi:10.1016/j.injury.2020.03.022

Cited by 17 publications

(11 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a recent study, using a rabbit model, Bami et al highlighted the superiority of SM-MSCs in terms of chondrogenesis, osteogenesis, myogenesis, and tenogenesis [ 14 ]. A study of xenogenic implantation of SM-MSCs in equine articular defects also confirmed better healing of the cartilage of affected knees as well as a higher expression of collagen type II, indicating the presence of hyaline cartilage in the healed defect [ 15 ].…”

Section: Introductionmentioning

confidence: 99%

Allogenic Synovia-Derived Mesenchymal Stem Cells for Treatment of Equine Tendinopathies and Desmopathies—Proof of Concept

Reis

Lopes

Sousa

et al. 2023

Animals

View full text Add to dashboard Cite

Tendon and ligament injuries are frequent in sport horses and humans, and such injuries represent a significant therapeutic challenge. Tissue regeneration and function recovery are the paramount goals of tendon and ligament lesion management. Nowadays, several regenerative treatments are being developed, based on the use of stem cell and stem cell-based therapies. In the present study, the preparation of equine synovial membrane mesenchymal stem cells (eSM-MSCs) is described for clinical use, collection, transport, isolation, differentiation, characterization, and application. These cells are fibroblast-like and grow in clusters. They retain osteogenic, chondrogenic, and adipogenic differentiation potential. We present 16 clinical cases of tendonitis and desmitis, treated with allogenic eSM-MSCs and autologous serum, and we also include their evaluation, treatment, and follow-up. The concerns associated with the use of autologous serum as a vehicle are related to a reduced immunogenic response after the administration of this therapeutic combination, as well as the pro-regenerative effects from the growth factors and immunoglobulins that are part of its constitution. Most of the cases (14/16) healed in 30 days and presented good outcomes. Treatment of tendon and ligament lesions with a mixture of eSM-MSCs and autologous serum appears to be a promising clinical option for this category of lesions in equine patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Allogenic Synovia-Derived Mesenchymal Stem Cells for Treatment of Equine Tendinopathies and Desmopathies—Proof of Concept

Reis

Lopes

Sousa

et al. 2023

Animals

View full text Add to dashboard Cite

show abstract

“…[ 50 ] MSCs present in cancerous tissue stroma play a key role in the proliferation of cancer cells, metastases, and resistance to chemotherapy. [ 51 ] MSCs are found in many tissues such as the umbilical cord, peripheral blood, skeletal muscle, adipose tissue,[ 52 ] dermis,[ 53 ] and synovial membrane. [ 54 ] MSCs are positive for CD105, CD73, and CD90, and negative for CD45, CD34, CD14, or CD11b, CD79, or CD19, and HLA-DR molecules.…”

Section: Msc S and T Heir D ...mentioning

confidence: 99%

“…[ 69 70 ] ADSCs promote the development of breast cancer by releasing cytokines such as CXCL1 and CXCL8. [ 43 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 70 71 72 ] MSCs with IL6 secretion increase endothelin 1 in the tumor, thereby stimulating ECs and causing angiogenesis. [ 65 ] ADSCs secrete angiogenic factors such as HGF.…”

Section: Msc S and T Heir D ...mentioning

confidence: 99%

The Effect of Stem Cells and Vascular Endothelial Growth Factor on Cancer Angiogenesis

Hashemibeni

Moradi-Gharibvand

2023

Advanced Biomedical Research

View full text Add to dashboard Cite

The formation of new vessels from pre-existing vessels is known as angiogenesis. The process is controlled by stimuli and inhibitors. Angiogenesis starts as a result of the unbalance of these factors, where balance has a tendency toward the stimulus. One of the most important factors promoting angiogenesis is the vascular endothelial growth factor (VEGF). In addition to being involved in vascular regeneration in normal tissues, VEGF also takes part in tumor tissue angiogenesis. These factors affect endothelial cells (ECs) directly as well as differentiate tumor cells from endothelial cells and play an active role in tumor tissue angiogenesis. Angiogenesis partakes in the growth and proliferation of tumor tissue. Because anti-angiogenic treatment is favorable in existing cancer therapies, the potential benefits should be considered. One of these new therapies is cell therapy using mesenchymal stem cells (MSCs). Research on MSCs remains controversial because much of the earlier research on MSCs has shown their effectiveness, but more recent research has identified harmful effects of these cells. This article reviews the role of stem cells and their secretions in the angiogenesis of tumor tissues.

show abstract

“…In six OA patients, Mizuno et al observed a greater proliferation and chondrogenesis in the MSCs present in the perivascular region of the synovium, whereas poorer chondrogenesis was observed in the MSCs from the stromal part of the synovium [102]. In a rabbit model, Bami et al demonstrated osteogenesis, chondrogenesis, myogenesis, and ethnogenesis with Sy-MSCs [103]. Fibrous synovium contains more MSCs than adipose synovium.…”

Section: Synovium-derived Mscs (Sy-mscs)mentioning

confidence: 99%

Lineage Differentiation Potential of Different Sources of Mesenchymal Stem Cells for Osteoarthritis Knee

et al. 2022

View full text Add to dashboard Cite

Tissue engineering and regenerative medicine (TERM) have paved a way for treating musculoskeletal diseases in a minimally invasive manner. The regenerative medicine cocktail involves the usage of mesenchymal stem/stromal cells (MSCs), either uncultured or culture-expanded cells along with growth factors, cytokines, exosomes, and secretomes to provide a better regenerative milieu in degenerative diseases. The successful regeneration of cartilage depends on the selection of the appropriate source of MSCs, the quality, quantity, and frequency of MSCs to be injected, and the selection of the patient at an appropriate stage of the disease. However, confirmation on the most favorable source of MSCs remains uncertain to clinicians. The lack of knowledge in the current cellular treatment is uncertain in terms of how beneficial MSCs are in the long-term or short-term (resolution of pain) and improved quality of life. Whether MSCs treatments have any superiority, exists due to sources of MSCs utilized in their potential to objectively regenerate the cartilage at the target area. Many questions on source and condition remain unanswered. Hence, in this review, we discuss the lineage differentiation potentials of various sources of MSCs used in the management of knee osteoarthritis and emphasize the role of tissue engineering in cartilage regeneration.

show abstract

Superiority of synovial membrane mesenchymal stem cells in chondrogenesis, osteogenesis, myogenesis and tenogenesis in a rabbit model

Cited by 17 publications

References 37 publications

Allogenic Synovia-Derived Mesenchymal Stem Cells for Treatment of Equine Tendinopathies and Desmopathies—Proof of Concept

Allogenic Synovia-Derived Mesenchymal Stem Cells for Treatment of Equine Tendinopathies and Desmopathies—Proof of Concept

The Effect of Stem Cells and Vascular Endothelial Growth Factor on Cancer Angiogenesis

Lineage Differentiation Potential of Different Sources of Mesenchymal Stem Cells for Osteoarthritis Knee

Contact Info

Product

Resources

About